Northern Trust Corp trimmed its stake in shares of Bausch Health Companies Inc (NYSE:BHC) by 1.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 361,703 shares of the company’s stock after selling 4,922 shares during the period. Northern Trust Corp owned approximately 0.10% of Bausch Health Companies worth $6,681,000 at the end of the most recent reporting period.
Other hedge funds also recently made changes to their positions in the company. Lindbrook Capital LLC acquired a new position in shares of Bausch Health Companies during the fourth quarter worth approximately $41,000. Contravisory Investment Management Inc. acquired a new position in shares of Bausch Health Companies during the fourth quarter worth approximately $104,000. Quadrant Capital Group LLC lifted its position in shares of Bausch Health Companies by 25.6% during the fourth quarter. Quadrant Capital Group LLC now owns 5,950 shares of the company’s stock worth $105,000 after purchasing an additional 1,211 shares in the last quarter. Enlightenment Research LLC acquired a new position in shares of Bausch Health Companies during the fourth quarter worth approximately $133,000. Finally, Amussen Hunsaker Associates LLC acquired a new position in shares of Bausch Health Companies during the third quarter worth approximately $148,000. Institutional investors own 54.67% of the company’s stock.
Shares of NYSE BHC opened at $24.13 on Wednesday. Bausch Health Companies Inc has a fifty-two week low of $16.91 and a fifty-two week high of $28.45. The company has a market capitalization of $8.44 billion, a P/E ratio of 6.00, a price-to-earnings-growth ratio of 0.58 and a beta of 0.59. The company has a current ratio of 1.10, a quick ratio of 0.85 and a debt-to-equity ratio of 8.55.
Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings data on Wednesday, February 20th. The company reported $1.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.84 by $0.21. Bausch Health Companies had a negative net margin of 50.83% and a positive return on equity of 39.91%. The business had revenue of $2.12 billion for the quarter, compared to analyst estimates of $2.08 billion. During the same period in the prior year, the business posted $0.98 earnings per share. Bausch Health Companies’s revenue was down 1.9% compared to the same quarter last year. Research analysts predict that Bausch Health Companies Inc will post 3.92 EPS for the current fiscal year.
BHC has been the topic of a number of research reports. Piper Jaffray Companies upgraded shares of Bausch Health Companies from a “neutral” rating to an “overweight” rating and set a $27.00 target price on the stock in a research report on Tuesday, January 1st. UBS Group upgraded shares of Bausch Health Companies to a “buy” rating in a research report on Wednesday, January 2nd. ValuEngine upgraded shares of Bausch Health Companies from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 2nd. Mizuho reiterated a “buy” rating and set a $39.00 target price on shares of Bausch Health Companies in a research report on Sunday, January 6th. Finally, Zacks Investment Research lowered shares of Bausch Health Companies from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 8th. Five research analysts have rated the stock with a sell rating, four have given a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $27.36.
In other Bausch Health Companies news, CEO Joseph C. Papa acquired 30,000 shares of the business’s stock in a transaction that occurred on Thursday, February 28th. The shares were acquired at an average cost of $23.67 per share, for a total transaction of $710,100.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 11.87% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Bausch Health Companies Inc (BHC) Shares Sold by Northern Trust Corp” was posted by Macon Daily and is the sole property of of Macon Daily. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://macondaily.com/2019/04/17/bausch-health-companies-inc-bhc-shares-sold-by-northern-trust-corp.html.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Further Reading: Different Options Trading Strategies
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.